Overview Dividends

(ANGO) AngioDynamics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03475V1017

Atherectomy, Thrombectomy, Ablation, Catheters, Guidewires, Drainage

ANGO EPS (Earnings per Share)

EPS Growth (3Y CAGR): -30.37%
EPS Trend (3Y Correlation): -17.4%

ANGO Revenue

Revenue Growth (3Y CAGR): -4.30%
Revenue Trend (3Y Correlation): -59.8%

Risk via 10d forecast
Volatility	52.4%
Value at Risk 5%th	71.9%
Relative Tail Risk	-16.55%

Reward TTM
Sharpe Ratio	1.08
Alpha	52.09

Character TTM
Hurst Exponent	0.493
Beta	0.961
Beta Downside	1.263

Drawdowns 3y
Max DD	65.96%
Mean DD	42.43%
Median DD	43.35%

Description: ANGO AngioDynamics October 25, 2025

AngioDynamics, Inc. (NASDAQ: ANGO) is a U.S.–based medical-technology firm that designs, manufactures, and markets devices for peripheral vascular disease, oncology, and surgical applications, serving both domestic and international customers.

The company’s portfolio includes the Auryon Atherectomy system for precise lesion removal, the AlphaVac mechanical thrombectomy device that operates without perfusionist support, and a suite of thrombolytic catheters for clot dissolution in dialysis grafts, arteries, veins, and surgical bypasses. Its AngioVac venous drainage cannula and extracorporeal circuit enable up to six-hour circulatory-support procedures, while the NanoKnife IRE Ablation System offers non-thermal soft-tissue ablation. Additional offerings span peripheral angiographic catheters, guidewires, micro-introducer kits, drainage catheters, the VenaCure EVLT laser system for superficial venous disease, and the Solero microwave tissue-ablation platform.

Key performance indicators from the most recent fiscal year show revenue of roughly $440 million, a cash balance of $120 million, and a gross margin near 55 %. The peripheral vascular device market is projected to grow at a 6-8 % CAGR through 2030, driven by an aging population, rising prevalence of peripheral artery disease, and expanding reimbursement for minimally invasive procedures-factors that directly support AngioDynamics’ growth outlook.

For a deeper, data-driven valuation, you might explore ValueRay’s analyst tools, which compile consensus forecasts and comparable peer metrics.

ANGO Stock Overview

Market Cap in USD	506m
Sub-Industry	Health Care Equipment
IPO / Inception	2004-05-27
Return 12m vs S&P 500	54.5%
Analyst Rating	4.67 of 5

ANGO Dividends

Currently no dividends paid

ANGO Growth Ratios

CAGR 3y	-3.82%
CAGR/Max DD Calmar Ratio	-0.06
CAGR/Mean DD Pain Ratio	-0.09
Current Volume	290.8k
Average Volume	400.1k

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (-32.1m TTM) > 0 and > 6% of Revenue (6% = 18.0m TTM)

FCFTA -0.04 (>2.0%) and ΔFCFTA 4.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 29.39% (prev 32.76%; Δ -3.37pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.03 (>3.0%) and CFO -7.79m > Net Income -32.1m (YES >=105%, WARN >=100%)

Net Debt (-38.8m) to EBITDA (1.79m) ratio: -21.70 <= 3.0 (WARN <= 3.5)

Current Ratio 2.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (41.2m) change vs 12m ago 1.28% (target <= -2.0% for YES)

Gross Margin 54.15% (prev 51.71%; Δ 2.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 107.5% (prev 99.69%; Δ 7.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5812 (EBITDA TTM 1.79m / Interest Expense TTM 4000 ) >= 6 (WARN >= 3)

Altman Z'' -9.10

(A) 0.33 = (Total Current Assets 156.7m - Total Current Liabilities 68.3m) / Total Assets 265.6m

(B) -1.66 = Retained Earnings (Balance) -440.1m / Total Assets 265.6m

warn (B) unusual magnitude: -1.66 — check mapping/units

(D) -5.07 = Book Value of Equity -439.7m / Total Liabilities 86.8m

Total Rating: -9.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.90

1. Piotroski 4.0pt = -1.0

2. FCF Yield -2.52% = -1.26

3. FCF Margin -3.95% = -1.48

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda -21.70 = 2.50

6. ROIC - WACC (= -20.34)% = -12.50

7. RoE -17.48% = -2.50

8. Rev. Trend -59.82% = -4.49

9. EPS Trend -17.43% = -0.87

What is the price of ANGO shares?

As of November 14, 2025, the stock is trading at USD 12.30 with a total of 290,759 shares traded.
Over the past week, the price has changed by +4.86%, over one month by +10.51%, over three months by +35.76% and over the past year by +75.97%.

Is AngioDynamics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, AngioDynamics (NASDAQ:ANGO) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 30.90 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANGO is around 12.71 USD . This means that ANGO is currently overvalued and has a potential downside of 3.33%.

Is ANGO a buy, sell or hold?

AngioDynamics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ANGO.

Strong Buy: 2
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ANGO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	18.5	50.4%
Analysts Target Price	18.5	50.4%
ValueRay Target Price	14.1	14.4%

ANGO Fundamental Data Overview November 11, 2025

Market Cap USD = 505.9m (505.9m USD * 1.0 USD.USD)
P/E Forward = 96.1538
P/S = 1.6824
P/B = 2.8287
P/EG = 1.87
Beta = 0.492
Revenue TTM = 300.7m USD
EBIT TTM = -23.2m USD
EBITDA TTM = 1.79m USD
Long Term Debt = unknown (none)
Short Term Debt = 1.84m USD (from shortTermDebt, last fiscal year)
Debt = 3.95m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -38.8m USD (from netDebt column, last quarter)
Enterprise Value = 471.1m USD (505.9m + Debt 3.95m - CCE 38.8m)
Interest Coverage Ratio = -5812 (Ebit TTM -23.2m / Interest Expense TTM 4000 )
FCF Yield = -2.52% (FCF TTM -11.9m / Enterprise Value 471.1m)
FCF Margin = -3.95% (FCF TTM -11.9m / Revenue TTM 300.7m)
Net Margin = -10.67% (Net Income TTM -32.1m / Revenue TTM 300.7m)
Gross Margin = 54.15% ((Revenue TTM 300.7m - Cost of Revenue TTM 137.9m) / Revenue TTM)
Gross Margin QoQ = 55.29% (prev 52.67%)
Tobins Q-Ratio = 1.77 (Enterprise Value 471.1m / Total Assets 265.6m)
Interest Expense / Debt = 0.10% (Interest Expense 4000 / Debt 3.95m)
Taxrate = -0.60% (negative due to tax credits) (65.0k / -10.8m)
NOPAT = -23.4m (EBIT -23.2m * (1 - -0.60%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.29 (Total Current Assets 156.7m / Total Current Liabilities 68.3m)
Debt / Equity = 0.02 (Debt 3.95m / totalStockholderEquity, last quarter 178.9m)
Debt / EBITDA = -21.70 (Net Debt -38.8m / EBITDA 1.79m)
Debt / FCF = 3.26 (negative FCF - burning cash) (Net Debt -38.8m / FCF TTM -11.9m)
Total Stockholder Equity = 183.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.08% (Net Income -32.1m / Total Assets 265.6m)
RoE = -17.48% (Net Income TTM -32.1m / Total Stockholder Equity 183.6m)
RoCE = -11.78% (EBIT -23.2m / Capital Employed (Total Assets 265.6m - Current Liab 68.3m))
RoIC = -12.57% (negative operating profit) (NOPAT -23.4m / Invested Capital 186.1m)
WACC = 7.77% (E(505.9m)/V(509.9m) * Re(7.83%) + D(3.95m)/V(509.9m) * Rd(0.10%) * (1-Tc(-0.01)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 1.18%
Fair Price DCF = unknown (Cash Flow -11.9m)
EPS Correlation: -17.43 | EPS CAGR: -30.37% | SUE: 0.34 | # QB: 0
Revenue Correlation: -59.82 | Revenue CAGR: -4.30% | SUE: 0.68 | # QB: 0

Additional Sources for ANGO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle